Pharma stocks in good health; Divi’s Labs, Lupin jump up to 3%

NEW DELHI: Gains in shares of Divi’s Laboratories (up 2.94 per cent), Lupin (up 2.30 per cent) and Cadila Healthcare (up 1.79 per cent) lifted Nifty Pharma index up in morning trade on Thursday.

Lupin’s US arm is recalling 11,706 bottles of Lisinopril tablets, used for treating hypertension, from the American market, USFDA said. The product being recalled by Lupin Pharmaceuticals Inc is in the strength of 10mg, the US health regulator said in an Enforcement Report.

The Nifty Pharma index was trading 0.97 per cent up at 10,047 around 10:30 am.

Dr. Reddy’s Laboratories (up 1.74 per cent), Cipla (up 1.71 per cent) and Aurobindo Pharma (up 1.66 per cent) too were trading with gains.

However, Piramal Enterprises (down 0.96 per cent) and Glenmark Pharmaceuticals (down 0.30 per cent) were trading in the red, whereas shares of Sun Pharmaceutical Industries (up 0.09 per cent) and Biocon (up 0.01 per cent) were almost flat around that time.

Market came down from record highs on selling in bank, metal and auto stocks.

Benchmark NSE Nifty50 index was down 9 points at 11,561, while the BSE Sensex was 7 points down at 38,279.25.

Among the 50 stocks in the Nifty index, 25 were trading in the green, while 25 were in the red.

HDFC, Hindustan Unilever and Reliance Industries were trading up in the Nifty index.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’